Loading clinical trials...
Loading clinical trials...
A Proof-of-concept, Biomarker-driven, Phase-II Clinical Trial to Explore the Activity of Decitabine Repurposing Against Advanced, Refractory, KRAS-dependent Pancreatic Ductal Adenocarcinoma (PDAC):The ORIENTATE Trial
Conditions
Interventions
Decitabine 50 MG [Dacogen]
Locations
6
Italy
Irccs S. Raffaele - Milano
Milan, Italy
Istituto Nazionale Tumori Di Napoli Irccs Pascale
Naples, Italy
Azienda Ospedaliero-Universitaria Pisana
Pisa, Italy
Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
Rome, Italy
Policlinico A. Gemelli E C.I.C.- Policlinico Universitario A. Gemelli
Rome, Italy
Az.Osp.Universitaria Integrata Verona- Borgo Roma
Verona, Italy
Start Date
January 15, 2022
Primary Completion Date
October 10, 2024
Completion Date
October 10, 2024
Last Updated
March 24, 2025
NCT06747845
NCT01053013
NCT01715142
NCT02179970
NCT03529175
NCT02195180
Lead Sponsor
Luca Cardone
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions